AIM: To study the effects of mesenchymal stem cell (MSC) therapy on the prevention of acute rejection and graft vs host disease following small bowel transplantation. METHODS: In our transplantation center, 6 isolated intestinal transplants have been performed with MSC therapy since 2009. The primary reasons for transplants were short gut syndrome caused by surgical intestine resection for superior mesenteric artery thrombosis (n = 4), Crohn's disease (n = 1) and intestinal aganglionosis (n = 1). Two of the patients were children. At the time of reperfusion, the first dose of MSCs cultured from the patient's bone marrow was passed into the transplanted intestinal artery at a dose of 1000000 cells/kg. The second and third doses of MSCs were given directly into the mesenteric artery through the arterial anastomosis using an angiography catheter on day 15 and 30 post-transplant. RESULTS: The median follow-up for these patients was 10.6 mo (min: 2 mo-max: 30 mo). Three of the patients developed severe acute rejection. One of these patients did not respond to bolus steroid therapy. Although the other two patients did respond to anti-rejection treatment, they developed severe fungal and bacterial infections. All of these patients died in the 2(nd) and 3(rd) months post-transplant due to sepsis. The remaining patients who did not have acute rejection had good quality of life with no complications observed during the follow-up period. In addition, their intestinal grafts were functioning properly in the 13(th), 25(th) and 30(th) month post-transplant. The patients who survived did not encounter any problems related to MSC transplantation. CONCLUSION: Although this is a small case series and not a randomized study, it is our opinion that small bowel transplantation is an effective treatment for intestinal failure, and MSC therapy may help to prevent acute rejection and graft vs host disease following intestinal transplantation.
AIM: To study the effects of mesenchymal stem cell (MSC) therapy on the prevention of acute rejection and graft vs host disease following small bowel transplantation. METHODS: In our transplantation center, 6 isolated intestinal transplants have been performed with MSC therapy since 2009. The primary reasons for transplants were short gut syndrome caused by surgical intestine resection for superior mesenteric artery thrombosis (n = 4), Crohn's disease (n = 1) and intestinal aganglionosis (n = 1). Two of the patients were children. At the time of reperfusion, the first dose of MSCs cultured from the patient's bone marrow was passed into the transplanted intestinal artery at a dose of 1000000 cells/kg. The second and third doses of MSCs were given directly into the mesenteric artery through the arterial anastomosis using an angiography catheter on day 15 and 30 post-transplant. RESULTS: The median follow-up for these patients was 10.6 mo (min: 2 mo-max: 30 mo). Three of the patients developed severe acute rejection. One of these patients did not respond to bolus steroid therapy. Although the other two patients did respond to anti-rejection treatment, they developed severe fungal and bacterial infections. All of these patients died in the 2(nd) and 3(rd) months post-transplant due to sepsis. The remaining patients who did not have acute rejection had good quality of life with no complications observed during the follow-up period. In addition, their intestinal grafts were functioning properly in the 13(th), 25(th) and 30(th) month post-transplant. The patients who survived did not encounter any problems related to MSC transplantation. CONCLUSION: Although this is a small case series and not a randomized study, it is our opinion that small bowel transplantation is an effective treatment for intestinal failure, and MSC therapy may help to prevent acute rejection and graft vs host disease following intestinal transplantation.
Entities:
Keywords:
Acute rejection; Mesenchymal stem cells; Short gut syndrome; Small bowel transplantation; Stem cell therapy
Authors: O Goulet; Y Révillon; D Jan; N Brousse; S De Potter; N Cerf-Bensussan; C Rambaud; C Buisson; D Pellerin; J F Mougenot Journal: Transplant Proc Date: 1990-12 Impact factor: 1.066
Authors: R G Lee; K Nakamura; A C Tsamandas; K Abu-Elmagd; H Furukawa; W R Hutson; J Reyes; J S Tabasco-Minguillan; S Todo; A J Demetris Journal: Gastroenterology Date: 1996-06 Impact factor: 22.682
Authors: Marjan Boerma; Junru Wang; Alexander F Burnett; Alessandro D Santin; Juan J Roman; Martin Hauer-Jensen Journal: Cancer Res Date: 2007-10-01 Impact factor: 12.701
Authors: Yang Yang; Hong Li Song; Wen Zhang; Ben Juan Wu; Nan Nan Fu; Chong Dong; Zhong Yang Shen Journal: Stem Cell Res Ther Date: 2016-11-20 Impact factor: 6.832
Authors: Jorge Zorzopulos; Steven M Opal; Andrés Hernando-Insúa; Juan M Rodriguez; Fernanda Elías; Juan Fló; Ricardo A López; Norma A Chasseing; Victoria A Lux-Lantos; Maria F Coronel; Raul Franco; Alejandro D Montaner; David L Horn Journal: World J Stem Cells Date: 2017-03-26 Impact factor: 5.326